Free Trial

XTL Biopharmaceuticals (XTLB) Competitors

XTL Biopharmaceuticals logo
$1.57 -0.03 (-1.88%)
Closing price 11/13/2026 03:53 PM Eastern
Extended Trading
$1.57 0.00 (0.00%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XTLB vs. JSPR, NEUP, KYNB, APLT, and ABOS

Should you buy XTL Biopharmaceuticals stock or one of its competitors? XTL Biopharmaceuticals's main competitors and comparable companies include Jasper Therapeutics (JSPR), Neuphoria Therapeutics (NEUP), Kyntra Bio (KYNB), Applied Therapeutics (APLT), and Acumen Pharmaceuticals (ABOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does XTL Biopharmaceuticals compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

XTL Biopharmaceuticals has higher revenue and earnings than Jasper Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/A-$75.80M-$47.75N/A
XTL Biopharmaceuticals$450K8.27-$6.97M-$0.64N/A

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Jasper Therapeutics had 2 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.82 beat Jasper Therapeutics' score of 0.44 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Jasper Therapeutics Neutral
XTL Biopharmaceuticals Very Positive

Jasper Therapeutics presently has a consensus target price of $220.00, indicating a potential upside of 1,508.19%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Jasper Therapeutics is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jasper Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
XTL Biopharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Jasper Therapeutics has a beta of 3.3, meaning that its share price is 230% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

XTL Biopharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A -884.17% -143.83%
XTL Biopharmaceuticals N/A N/A N/A

Summary

Jasper Therapeutics and XTL Biopharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 1.6% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.82 beat Neuphoria Therapeutics' score of 0.39 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Neuphoria Therapeutics Neutral
XTL Biopharmaceuticals Very Positive

Neuphoria Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 174.51%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Neuphoria Therapeutics is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
XTL Biopharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

XTL Biopharmaceuticals has lower revenue, but higher earnings than Neuphoria Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$1.17M11.79-$13.45M-$6.22N/A
XTL Biopharmaceuticals$450K8.27-$6.97M-$0.64N/A

Neuphoria Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

XTL Biopharmaceuticals' return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -38.31% -28.92%
XTL Biopharmaceuticals N/A N/A N/A

Summary

Neuphoria Therapeutics and XTL Biopharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Kyntra Bio?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Kyntra Bio has higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XTL Biopharmaceuticals$450K8.27-$6.97M-$0.64N/A
Kyntra Bio$6.44M2.16$183.45M$45.300.08

Kyntra Bio has a net margin of 2,199.13% compared to XTL Biopharmaceuticals' net margin of 0.00%.

Company Net Margins Return on Equity Return on Assets
XTL BiopharmaceuticalsN/A N/A N/A
Kyntra Bio 2,199.13%N/A -47.27%

Kyntra Bio has a consensus target price of $36.80, suggesting a potential upside of 969.77%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XTL Biopharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

XTL Biopharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

In the previous week, Kyntra Bio had 3 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Kyntra Bio and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.82 beat Kyntra Bio's score of 0.76 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
XTL Biopharmaceuticals Very Positive
Kyntra Bio Positive

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Kyntra Bio beats XTL Biopharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Applied Therapeutics currently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Applied Therapeutics is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
XTL Biopharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

XTL Biopharmaceuticals' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -340.84% -175.00%
XTL Biopharmaceuticals N/A N/A N/A

Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

XTL Biopharmaceuticals has lower revenue, but higher earnings than Applied Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A
XTL Biopharmaceuticals$450K8.27-$6.97M-$0.64N/A

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for XTL Biopharmaceuticals and 0 mentions for Applied Therapeutics. XTL Biopharmaceuticals' average media sentiment score of 1.82 beat Applied Therapeutics' score of 0.00 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Therapeutics Neutral
XTL Biopharmaceuticals Very Positive

Summary

Applied Therapeutics beats XTL Biopharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Acumen Pharmaceuticals?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

XTL Biopharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than Acumen Pharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XTL Biopharmaceuticals$450K8.27-$6.97M-$0.64N/A
Acumen PharmaceuticalsN/AN/A-$121.33M-$1.54N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
XTL BiopharmaceuticalsN/A N/A N/A
Acumen Pharmaceuticals N/A -166.49%-90.79%

Acumen Pharmaceuticals has a consensus target price of $1.00, indicating a potential upside of 367.29%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XTL Biopharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Acumen Pharmaceuticals
3 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.71

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 2 mentions for Acumen Pharmaceuticals and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.82 beat Acumen Pharmaceuticals' score of 0.41 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
XTL Biopharmaceuticals Very Positive
Acumen Pharmaceuticals Neutral

Summary

XTL Biopharmaceuticals beats Acumen Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XTLB vs. The Competition

MetricXTL BiopharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.72M$4.13B$7.89B$12.08B
Dividend YieldN/A3.64%2.47%4.53%
P/E Ratio-2.4524.6434.5930.65
Price / Sales8.2716.298.665.81
Price / CashN/A21.8921.0222.32
Price / Book-14.274.504.803.95
Net Income-$6.97M-$24.19M$3.52B$391.64M
7 Day Performance-5.42%-4.44%-3.20%-2.48%
1 Month Performance-14.91%-2.06%-1.47%-3.98%
1 Year PerformanceN/A-1.72%1.46%-5.71%

XTL Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XTLB
XTL Biopharmaceuticals
0.9017 of 5 stars
$1.57
-1.9%
N/AN/A$3.72M$450KN/A10
JSPR
Jasper Therapeutics
1.9075 of 5 stars
$0.49
-4.9%
$7.33
+1,408.9%
-72.9%$16.21MN/AN/A22
NEUP
Neuphoria Therapeutics
1.9236 of 5 stars
$2.99
+0.3%
$7.00
+134.1%
-46.8%$16.18M$1.17MN/A1
KYNB
Kyntra Bio
3.85 of 5 stars
$4.08
+3.1%
$36.80
+801.3%
N/A$16.06M$6.44M0.0934
APLT
Applied Therapeutics
N/A$0.10
flat
$1.00
+870.9%
N/A$15.86M$1MN/A30

Related Companies and Tools


This page (NASDAQ:XTLB) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners